Home > Neopharm Salary

Neopharm Salary

  • 71
  • 90
  • 68
Neopharm average salary is $50,226, median salary is $49,750 with a salary range from $47,403 to $54,000.
Neopharm salaries are collected from government agencies and companies. Each salary is associated with a real job position. Neopharm salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 4 Neopharm Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Fundraising & Database Development Associate 54,000-54,000 New York, NY, 10001 2012 Neopharm Fundraising & Database Development Associate Salaries (2)
Neopharm New York, NY Salaries
Fundraising & Database Development Associate 50,500-50,500 New York, NY, 10001 2011 Neopharm Fundraising & Database Development Associate Salaries (2)
Neopharm New York, NY Salaries
Charge Nurse - Lpn 47,403-47,403 Bronx, NY, 10451 2010 Neopharm Charge Nurse - Lpn Salaries (1)
Neopharm Bronx, NY Salaries
Fundraising & Database Development Assistant 49,000-49,000 New York, NY, 10001 2010 Neopharm Fundraising & Database Development Assistant Salaries (1)
Neopharm New York, NY Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Neopharm salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Neopharm Jobs
See more Neopharm Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Neopharm... Information
  • Neopharm Inc
  • Industry: BioTech/Drugs
  • City: Lake Bluff, IL
  • NeoPharm, Inc. is a biopharmaceutical company engaged in the research, development and commercialization of drugs for the treatment of various cancers. The Company has built its drug portfolio based on its two novel proprietary technology platforms, the proprietary NeoLipid liposomal drug delivery system and a tumor-targeting toxin platform. NeoPharm has several promising compounds in various stages of development. The Company's lead compound is IL13-PE38, a tumor-targeting toxin being developed as a treatment for glioblastoma multiforme, a deadly form of brain cancer.